Literature DB >> 2552875

Cross-protective immunity between equine encephalomyelitis viruses in equids.

T E Walton1, M M Jochim, T L Barber, L H Thompson.   

Abstract

Eighteen equids were inoculated with eastern equine encephalomyelitis (EEE) and 18 equids with western equine encephalomyelitis (WEE) viruses to produce EEE virus- and WEE virus-immunized equids. Twelve surviving EEE virus-seropositive equids, 15 surviving WEE virus-seropositive equids, and 10 nonimmunized, seronegative equids (controls) were subsequently inoculated with an equine pathogenic (epizootic) strain of Venezuelan equine encephalomyelitis (VEE) virus to determine cross-protective immunity. Challenge infection produced 90% mortality in control (nonimmunized) equids, and 40% mortality in WEE virus-seropositive equids; all EEE virus-seropositive equids survived. Postchallenge exposure VEE viremia levels in EEE virus- or WEE virus-seropositive equids were lower than those in the 10 nonimmunized VEE virus-inoculated control equids. Plaque-neutralizing antibody responses to VEE virus in the EEE virus- and WEE virus-seropositive equids were similar in time of onset and titer to the antibody responses of nonimmunized equids. Neutralizing antibody to the third equine encephalomyelitis virus (either EEE virus or WEE virus) was detectable in 19 of 27 equids after inoculation with the challenge virus, VEE. Demonstration of cross-protective immunity between EEE or WEE virus and VEE virus in equids confirmed field observations made during the VEE epizootic in Texas in 1971.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552875

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

2.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 3.  Medically important arboviruses of the United States and Canada.

Authors:  C H Calisher
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

4.  The impact of coinfections and their simultaneous transmission on antigenic diversity and epidemic cycling of infectious diseases.

Authors:  Xu-Sheng Zhang; Ke-Fei Cao
Journal:  Biomed Res Int       Date:  2014-06-22       Impact factor: 3.411

5.  Neutralising antibodies for Mayaro virus in Pantanal, Brazil.

Authors:  Alex Pauvolid-Corrêa; Raquel Soares Juliano; Zilca Campos; Jason Velez; Rita Maria Ribeiro Nogueira; Nicholas Komar
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-03       Impact factor: 2.743

Review 6.  Equids' Core Vaccines Guidelines in North America: Considerations and Prospective.

Authors:  Hélène Desanti-Consoli; Juliette Bouillon; Ronan J J Chapuis
Journal:  Vaccines (Basel)       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.